Scholarlink

Objective <p>Brain metastases (BrM) among patients with gynecological cancers (GC) have historically been considered rare events, but incidence maybe rising. This study aims to understand treatment patterns and outcomes of patients with GCs and BrM.</p> Study methods <p>We conducted a retrospective analysis of patients with GCs and BrM who were treated with radiotherapy at Odette Cancer Centre, Canada, between 2010 and 2022. Descriptive statistics and survival analyses were performed using the R software.</p> Results <p>We identified 94 patients with BrM secondary to GCs. Median age at time of BrM diagnosis was 66 years; median time to BrM development was 30 months, and median follow up time was 7 months. Most patients (63.8%, <i>n</i> = 60) underwent stereotactic radiosurgery (SRS), and 40.4% (<i>n</i> = 38) also had surgery for BrM. Patients with endometrial cancer (EC) accounted for 54.3% (<i>n</i> = 51) of BrM cases followed by ovarian cancer (OC) (25.5%, <i>n</i> = 24) and cervical cancer (CC) (17%, <i>n</i> = 16). Molecular profiling when available revealed 83.3% of EC (<i>n</i> = 10/12) had TP53 overexpression and 33.3% (<i>n</i> = 4/12) had mismatch repair deficiency whereas 20% of OC patients (<i>n</i> = 2/10) had a germline <i>BRCA</i> mutation. Median overall survival (OS) was 10.6 months, longer for OC patients compared to those with EC or CC.</p> Conclusion <p>In our cohort of patients with GC and BrM treated with radiotherapy, about a third received surgery and two thirds of patients were treated with SRS. Patients with OC and BrM lived longer than those with other primary GCs. Investigation of molecular events that “drive” the development of BrM among patients with GCs is warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Brain metastases among patients with gynecologic cancers: a single-centre retrospective study of patients treated with brain radiotherapy

  • 期刊论文

  • 发表日期：

    2026年3月16日

查看全文
  • Rania Chehade,
  • Abdullah Al-Humiqani,
  • Lilian Hanna,
  • Arjun Sahgal,
  • Veronika Moravan,
  • Sunit Das,
  • Hany Soliman,
  • Helen Mackay,
  • Katarzyna J. Jerzak

摘要

Objective

Brain metastases (BrM) among patients with gynecological cancers (GC) have historically been considered rare events, but incidence maybe rising. This study aims to understand treatment patterns and outcomes of patients with GCs and BrM.

Study methods

We conducted a retrospective analysis of patients with GCs and BrM who were treated with radiotherapy at Odette Cancer Centre, Canada, between 2010 and 2022. Descriptive statistics and survival analyses were performed using the R software.

Results

We identified 94 patients with BrM secondary to GCs. Median age at time of BrM diagnosis was 66 years; median time to BrM development was 30 months, and median follow up time was 7 months. Most patients (63.8%, n = 60) underwent stereotactic radiosurgery (SRS), and 40.4% (n = 38) also had surgery for BrM. Patients with endometrial cancer (EC) accounted for 54.3% (n = 51) of BrM cases followed by ovarian cancer (OC) (25.5%, n = 24) and cervical cancer (CC) (17%, n = 16). Molecular profiling when available revealed 83.3% of EC (n = 10/12) had TP53 overexpression and 33.3% (n = 4/12) had mismatch repair deficiency whereas 20% of OC patients (n = 2/10) had a germline BRCA mutation. Median overall survival (OS) was 10.6 months, longer for OC patients compared to those with EC or CC.

Conclusion

In our cohort of patients with GC and BrM treated with radiotherapy, about a third received surgery and two thirds of patients were treated with SRS. Patients with OC and BrM lived longer than those with other primary GCs. Investigation of molecular events that “drive” the development of BrM among patients with GCs is warranted.